Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia
18 Years
N/A
Both
Lymphoma
Trial Information
Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia
OBJECTIVES:
- Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's
macroglobulinemia (WM) for potential future use in transplantation strategies.
- Evaluate the ability to harvest stem cells after therapy for WM (e.g.,
fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest.
- Collect aliquots of stem cells for future research analysis as part of a WM database
project.
OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and
continuing until an adequate number of stem cells are collected. Cells are then
cryopreserved.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of Waldenstrom's macroglobulinemia (WM)
- Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology
- Received prior chemotherapy for WM
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- WBC > 2,000/mm³
- Platelet count > 50,000/mm³
- LVEF ≥ 50%
- No organ dysfunction that would preclude future transplantation
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Number of days to adequate stem cell harvest
Safety Issue:
No
Principal Investigator
Gwen L. Nichols, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Herbert Irving Comprehensive Cancer Center
Authority:
Unspecified
Study ID:
CDR0000487602
NCT ID:
NCT00899119
Start Date:
November 2005
Completion Date:
Related Keywords:
- Lymphoma
- Waldenström macroglobulinemia
- Lymphoma
- Waldenstrom Macroglobulinemia
Name | Location |
|---|---|
| Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | New York, New York 10032 |
